Nanotech, Single-Molecule Methods, Personalized Medicine Remain Top of Mind for VCs | GenomeWeb

This is part two of a two-part series examining the venture capital landscape in the life science research tools and molecular diagnostics markets. To read part one, click here.

NEW YORK (GenomeWeb News) – Despite the recently soured economy, venture capitalists have remained relatively optimistic about investment opportunities in the life science research tools and molecular diagnostics sectors, according to industry insiders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.